byiShook Opinion
Mar 10, 2025 - 12:10
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study. The post Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. appeared first on Investor's Business Daily.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
The post Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. appeared first on Investor's Business Daily.